Fig. 2From: Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN)Patient disposition. PP, per-protocol; PR, prolonged release; ITT, intention-to-treat. *Includes re-screened patients (n = 15)Back to article page